Glenn J. Hanna, MD
Dana-Farber Cancer Institute
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Glenn J. Hanna, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:20 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT04832438 · 9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland CarcinomaActuate Therapeutics Inc. · withdrawn · Salivary Gland Carcinoma, Adenoid Cystic Carcinoma, Salivary Gland Cancer
- Ph2NCT04620187 · Post-op T-DM1 in HER-2+ Salivary Gland CarcinomasDana-Farber Cancer Institute · recruiting · Salivary Gland Cancer, HER2 Gene Mutation
- Ph1/Ph2NCT04339062 · Cemiplimab in AlloSCT/SOT Recipients With CSCCDana-Farber Cancer Institute · completed · Cutaneous Squamous Cell Carcinoma, Advanced Cancer
- Ph2NCT03999684 · A Trial of All-trans Retinoic Acid (ATRA) in Advanced Adenoid Cystic CarcinomaDana-Farber Cancer Institute · completed · Adenoid Cystic Carcinoma · principal investigator
- Ph2NCT03341936 · Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in SCCHNDana-Farber Cancer Institute · active not recruiting · Squamous Cell Carcinoma of the Head and Neck · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:20 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.